Talking Therapeutics is a weekly column written by Douglas Jennings, PharmD. Dr Jennings tackles timely therapeutic topics by breaking it down into bite-sized talking points. Each week, Dr Jennings will convey high-impact clinical material in a quick, fun, easy-to-read article.
Volume 1, Issue 1
In the first installment, Dr Jennings breaks down the COVID-19 vaccines, and explains how to discuss them with patients.
Volume 1, Issue 2
In this week’s column, Douglas Jennings, PharmD, looks at the latest updates on how heart failure is classified, and explores a novel treatment option for patients with heart failure with preserved ejection fraction.
Volume 1, Issue 3
This week Dr Jennings explores the latest evidence for two potential COVID-19 drug therapies, and discusses whether these therapy options belong on your drug therapy team.
Volume 1, Issue 4
Dr Jennings reviews two of the latest trials evaluating the controversial topic of fish oils products, and attempts to get the bottom of this murky pond of conflicted evidence.
Volume 2, Issue 1
In this week’s issue of Talking Therapeutics, Dr Jennings examine the latest study surrounding the murky subject of anticoagulating patients with severe COVID-19 infection, and what it means for frontline pharmacists practicing in the hospital setting.
Volume 2, Issue 2
When combining the high prevalence of hypertension with new aggressive treatment targets, a lot of patients may face the risk of having to take numerous drugs. In this week’s issue of Talking Therapeutics, Dr Jennings looks at a few recent and interesting articles surrounding this timely topic.
Volume 2, Issue 3
Dr Jennings reviews evidence supporting colchicine use to further reduce residual disease burden in coronary artery disease but highlights why pharmacists need to keep several things in mind when dispensing colchicine to ensure that patients are kept safe.